Dexcom Stock News

Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.

Dexcom (NSDQ:DXCM) announced that it received FDA breakthrough device designation for the use of its CGM in the hospital setting. The Dexcom continuous glucose monitor (CGM) uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device to provide real-time glucose data and eliminate the need for […] The post Dexcom wins FDA brekathrough nod for use of its CGM in hospitals appeared first on Drug Delivery Business .

The FDA granted Breakthrough Device Designation for DexCom Inc (NASDAQ: DXCM ) for continuous glucose monitoring (CGM) use in the hospital setting. Dexcom CGM uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device, providing real-time glucose data … Full story available on Benzinga.com

DexCom (DXCM) said the U.S. FDA granted Breakthrough Device Designation for Dexcom CGM use in the hospital setting.Dexcom CGM uses a small, wearable sensor and transmitter to…

The market for its products is huge.

The market for its products is huge.

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here.

Why are investors bullish on DexCom?

The S&P 500 is off almost 9% for the year-to-date, but the biggest decliners in the main benchmark of U.S. equity performance are faring far, far worse. From small, somewhat obscure members of the ind

The stock price of Dexcom, best known for its continuous glucose monitoring systems, has seen a drop of 8% over the last month, while it was down 5% on Friday, Feb 11, due to the company's downbeat Q4

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences: Brice Bobzien, Vice

DexCom Inc''s (NASDAQ: DXCM ) Q4 adjusted EPS of $0.68 was lower than $0.91 posted a year ago and missing the consensus of $0.85. Sales increased 23% Y/Y to $698.2 million, surpassing the consensus of $695.63 million, and grew 20% on an organic basis. Volume growth and strong new customer additions Full story available on Benzinga.com

Futures Reverse Overnight Rout As Doubts Emerge About Aggressive Fed Hiking After initially sinking sharply, with S&P futures dropping as much as 1% overnight on concerns that aggressive rate hikes from the Fed aimed at curbing stubbornly high inflation could plunge the US into recession and crash risk assets, US equity futures have recovered most of their losses after an overnight article from Bloomberg reported that the " Fed Doesn’t Yet Favor a Half-Point Hike or an Emergency Move " easing investor nerves that a massive hike is imminent. Contracts on the Nasdaq were also flat after earlier retreating as much as 1.2% as growth stocks are especially sensitive to rising rates and bond yields. Still, absent a powerful bounce today, the S&P 500 is set to snap a two-week winning streak. The benchmark S&P 500 has struggled to gain for three weeks in a row since November as the Fed signaled it was prepared to tighten monetary policy to rein in red-hot inflation, but strategists say a broader selloff across stock markets is unlikely.

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.

DXCM earnings call for the period ending December 31, 2021.